PredictCan Biotechnologies and PreClinBio Solutions LLP have entered into a strategic international collaboration aimed at combining complementary expertise in preclinical research, biotechnology, and precision medicine.
The partnership brings together PreClinBio’s integrated preclinical research capabilities in India and PredictCan’s individual-centric preclinical technologies in France, creating new opportunities to support pharmaceutical and biotechnology companies throughout drug development.
Combining Complementary Preclinical Expertise
Modern drug development increasingly requires preclinical strategies capable of integrating multiple sources of evidence while improving their relevance to human biology.
Through this collaboration, PredictCan and PreClinBio aim to combine their respective capabilities to develop advanced preclinical and translational solutions, connecting established preclinical expertise with emerging human-relevant approaches.
PredictCan contributes its expertise in individual-centric models, human biological diversity, drug safety and efficacy assessment, while the collaboration benefits from PreClinBio’s broader preclinical research capabilities.
Together, the partners aim to provide complementary approaches that can support compound evaluation, translational research, and more informed preclinical decision-making.
Strengthening India–Europe Biotechnology Collaboration
Beyond its scientific objectives, the partnership represents another step in PredictCan’s international development, strengthening connections between the biotechnology ecosystems of India and Europe.
The collaboration is intended to facilitate scientific exchange, explore joint development opportunities, and expand access to innovative preclinical technologies across international pharmaceutical and biotechnology markets.
It also reflects a shared commitment to advancing high-quality and regulatory-aligned research approaches capable of supporting the evolving needs of global drug development.
Advancing Human-Relevant Drug Development Worldwide
For PredictCan, this collaboration supports a broader strategy of building an international ecosystem around its technologies through partnerships with preclinical organizations, biotechnology companies, academic institutions, hospitals, and regulatory-oriented initiatives.
By combining complementary expertise across countries and disciplines, PredictCan aims to accelerate the transition toward preclinical strategies that are more human-relevant, predictive, and representative of biological diversity.
The partnership with PreClinBio Solutions therefore represents another step toward making these approaches accessible to drug developers internationally.
